You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

Dermatology

On demand events

Translating the Science of CSU: From Pathogenesis to Patient Outcomes

Watch as Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, importance of disease control, and emerging therapies.

MD, PhD

Michihiro Hide +2 more

Learning objectives

Understand the unmet needs and the importance of achieving and maintaining disease control in CSU
Discuss the latest advancements in CSU pathophysiology, including mast-cell activation pathways with demonstrated clinical relevance
Describe the latest data on CSU therapeutics and the potential future for CSU management

About these experts

Dermatology

MD, PhD

Michihiro Hide

Hiroshima City Hiroshima Citizens Hospital

Allergy/Immunology

MD, PhD

Marta Ferrer

Head of the Department of Allergy at Navarra University Hospital, Pamplona, Spain

Dermatology

MD, PhD

Ana Maria Giménez-Arnau

Associate Professor of Dermatology | Autonomous University and Pompeu Fabra University, Barcelona, Spain

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region